Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.50+0.12 (+3.55%)
Close on Nov 18, 2026Market cap $515.20MP/E –Yield –
Aclaris Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aclaris Therapeutics's total assets was $179.69M at Jun 30, 2026. For fiscal 2025 it was $160.46M, down 27.2% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is $275.57M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.46M | -27.2% |
| FY2024 | Dec 31, 2024 | $220.33M | +11.6% |
| FY2023 | Dec 31, 2023 | $197.41M | -22.5% |
| FY2022 | Dec 31, 2022 | $254.60M | +1.3% |
| FY2021 | Dec 31, 2021 | $251.21M | +254.9% |
| FY2020 | Dec 31, 2020 | $70.78M | -28.0% |
| FY2019 | Dec 31, 2019 | $98.30M | -64.3% |
| FY2018 | Dec 31, 2018 | $275.57M | +13.2% |
| FY2017 | Dec 31, 2017 | $243.51M | +38.3% |
| FY2016 | Dec 31, 2016 | $176.09M | +87.2% |
| FY2015 | Dec 31, 2015 | $94.08M | +441.4% |
| FY2014 | Dec 31, 2014 | $17.38M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $179.69M | -5.0% |
| Q1 FY2026 | Mar 31, 2026 | $198.72M | +0.3% |
| Q4 FY2025 | Dec 31, 2025 | $160.46M | -27.2% |
| Q3 FY2025 | Sep 30, 2025 | $175.53M | -3.8% |
| Q2 FY2025 | Jun 30, 2025 | $189.15M | +17.4% |
| Q1 FY2025 | Mar 31, 2025 | $198.09M | +13.8% |
| Q4 FY2024 | Dec 31, 2024 | $220.33M | +11.6% |
| Q3 FY2024 | Sep 30, 2024 | $182.39M | -16.5% |
| Q2 FY2024 | Jun 30, 2024 | $161.07M | -31.6% |
| Q1 FY2024 | Mar 31, 2024 | $174.07M | -24.2% |
| Q4 FY2023 | Dec 31, 2023 | $197.41M | -22.5% |
| Q3 FY2023 | Sep 30, 2023 | $218.35M | -18.4% |
| Q2 FY2023 | Jun 30, 2023 | $235.65M | -15.2% |
| Q1 FY2023 | Mar 31, 2023 | $229.71M | +1.4% |
| Q4 FY2022 | Dec 31, 2022 | $254.60M | +1.3% |
| Q3 FY2022 | Sep 30, 2022 | $267.63M | +1.6% |
| Q2 FY2022 | Jun 30, 2022 | $277.98M | -3.5% |
| Q1 FY2022 | Mar 31, 2022 | $226.53M | +40.4% |
| Q4 FY2021 | Dec 31, 2021 | $251.21M | +254.9% |
| Q3 FY2021 | Sep 30, 2021 | $263.49M | +266.5% |
| Q2 FY2021 | Jun 30, 2021 | $288.05M | +238.9% |
| Q1 FY2021 | Mar 31, 2021 | $161.40M | +66.7% |
| Q4 FY2020 | Dec 31, 2020 | $70.78M | -28.0% |
| Q3 FY2020 | Sep 30, 2020 | $71.90M | -55.2% |
| Q2 FY2020 | Jun 30, 2020 | $85.00M | -60.9% |
| Q1 FY2020 | Mar 31, 2020 | $96.81M | -61.8% |
| Q4 FY2019 | Dec 31, 2019 | $98.30M | -64.3% |
| Q3 FY2019 | Sep 30, 2019 | $160.42M | -8.9% |
| Q2 FY2019 | Jun 30, 2019 | $217.24M | +7.6% |
| Q1 FY2019 | Mar 31, 2019 | $253.18M | +14.8% |
| Q4 FY2018 | Dec 31, 2018 | $275.57M | +13.2% |
| Q3 FY2018 | Sep 30, 2018 | $176.18M | -32.6% |
| Q2 FY2018 | Jun 30, 2018 | $201.82M | +14.1% |
| Q1 FY2018 | Mar 31, 2018 | $220.62M | +32.7% |
| Q4 FY2017 | Dec 31, 2017 | $243.51M | +38.3% |
| Q3 FY2017 | Sep 30, 2017 | $261.39M | +203.7% |
| Q2 FY2017 | Jun 30, 2017 | $176.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $166.21M | – |
| Q4 FY2016 | Dec 31, 2016 | $176.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $86.07M | – |
See a number that looks wrong?